{"id":"W2955764585","doi":"","title":"Безопасность биологических препаратов. Сообщение 2. Проблемы безопасности биоподобных препаратов","year":2016,"lang":"ru","type":"article","venue":"Biological Products Prevention Diagnosis Treatment","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Pharmacovigilance; Medicine; Infliximab; Interchangeability; Ulcerative colitis; Inflammatory bowel disease; Marketing authorization; Disease; Intensive care medicine; Pharmacology; Drug; Internal medicine; Bioinformatics","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.001803172,0.00187098,0.002305108,0.0004010934,0.0008309379,0.000150411,0.001094699,0.002531237,0.0154217],"category_scores_gemma":[0.002312537,0.00102668,0.001511386,0.0009671995,0.002108088,0.0003769014,0.0006752801,0.0006404527,0.005118563],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00111197,"about_ca_system_score_gemma":0.0003851089,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001410239,"about_ca_topic_score_gemma":0.0000766269,"domain_scores_codex":[0.9877427,0.0036884,0.002201371,0.003597764,0.0003171135,0.002452655],"domain_scores_gemma":[0.993964,0.001961205,0.0009775499,0.002120728,0.0004974362,0.0004790566],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001594718,0.01626446,0.03838173,0.0001730521,0.004068367,0.0001616919,0.0001742679,9.532415e-7,0.07049406,0.008336676,0.05432185,0.8060282],"study_design_scores_gemma":[0.00670895,0.01072254,0.03260662,0.0008102988,0.001303599,0.00009599084,0.0001134828,0.000001575349,0.2197878,0.004245033,0.7218658,0.00173835],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5574266,0.1726961,0.002616556,0.2178557,0.0193108,0.01504368,0.003569661,0.002193967,0.009286862],"genre_scores_gemma":[0.8763809,0.05386767,0.004087504,0.001050747,0.001770075,0.001533643,0.0003337016,0.0001346563,0.06084113],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8042898,"threshold_uncertainty_score":0.9994035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.105695995460469,"score_gpt":0.3372912321613004,"score_spread":0.2315952367008313,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}